Clinical trials: Mild to Moderate Psoriasis
Psoriasis
Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis
This study assessed the safety and pharmacokinetics (PK) of a single dose application of ARQ-151 cream 0.5% to 25 cm^2 of psoriatic plaque(s) (Cohort 1).
- Trial name
- NCT03392168
- Testing
- ARQ-151 cream 0.5%, ARQ-151 cream 0.15%, ARQ-151 vehicle cream
- Where
- 8 sites in United States, Canada
- Volunteers
- 91 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Psoriasis Vulgaris
Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
The objective of this study is to evaluate the safety and efficacy of up to 26 weeks of treatment with calcitriol 3 mcg/g ointment when used twice daily, without occlusion, to treat pediatric subjects (2 to 16 years and 11 months…
- Trial name
- NCT02125279
- Testing
- Calcitriol
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 54 people
- Sponsor
- Galderma R&D
Plaque Psoriasis
A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults
The main aim of this study is to assess treatment satisfaction, quality of life, treatment preference, adherence and convenience, psychosocial effects of scalp psoriasis, sleep quality, and effectiveness, and safety of…
- Trial name
- PRO-SCALP (NCT05811234)
- Testing
- CAL/BDP PAD Cream
- Where
- 37 sites in Germany, Spain and 1 more
- Volunteers
- 291 people
- Sponsor
- Almirall, S.A.
Plaque Psoriasis
Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of 12 weeks of treatment with Apo805K1 in subjects with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01483924
- Testing
- Apo805K1
- Where
- 7 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- ApoPharma
Psoriasis
Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis.
- Trial name
- ADVANCE (NCT03721172)
- Testing
- Apremilast
- Where
- 64 sites in United States, Canada
- Volunteers
- 595 people
- Sponsor
- Amgen
Plaque Psoriasis
Plaque Psoriasis Study in Pediatric Subjects
The purpose of this study is to compare the safety, efficacy and calcium metabolism of up to 8 weeks of treatment with calcitriol 3 mcg/g ointment versus its vehicle, when used twice daily, without occlusion, to treat children…
- Trial name
- NCT02186665
- Testing
- calcitriol ointment
- Where
- 34 sites in United States, Belgium and 5 more
- Volunteers
- 19 people
- Sponsor
- Galderma R&D
Atopic Dermatitis, Plaque Psoriasis
Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis
This study is being conducted to provide data on efficacy, safety, tolerability and PK of PF-07038124 ointment versus vehicle control in the treatment of mild to moderate AD and mild to moderate plaque psoriasis.
- Trial name
- EMPORIA (NCT04664153)
- Testing
- PF-07038124 ointment, Vehicle ointment
- Where
- 29 sites in United States, Australia and 2 more
- Volunteers
- 104 people
- Sponsor
- Pfizer
Psoriasis
CP-690-550 Ointment For Chronic Plaque Psoriasis
The study is being conducted to see whether CP-690,550 ointment has potential as a safe and effective treatment for adult patients with mild to moderate chronic plaque psoriasis.
- Trial name
- NCT01246583
- Testing
- CP-690,550 Ointment 1, Vehicle 1, CP-690,550 Ointment 2
- Where
- 12 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- Pfizer
Psoriasis
Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis
The study is a randomized, double blinded, vehicle and active comparator controlled, multiple dose study in subjects with chronic plaque psoriasis. The study will have approximately 15 completers.
- Trial name
- NCT03469336
- Testing
- PF-06763809, Vehicle, Calcipotriene/calcipotriol
- Where
- 2 sites in Germany
- Volunteers
- 18 people
- Sponsor
- Pfizer
Plaque Psoriasis
Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis
The purpose of this study is to evaluate the therapeutic efficacy and safety of DSXS compared to a Placebo (vehicle) in patients with mild to moderate plaque psoriasis.
- Trial name
- NCT02618759
- Testing
- DSXS
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis Vulgaris
This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream
This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating the efficacy, safety and convenience of the MC2-01 cream.
- Trial name
- NCT03802344
- Testing
- MC2-01 cream, Cal/BDP combination, Vehicle
- Where
- 2 sites in Czechia, Germany
- Volunteers
- 498 people
- Sponsor
- MC2 Therapeutics
Psoriasis, Plaque Psoriasis
A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis
This Phase 2 study has been designed to investigate the clinical safety and efficacy of EDP1815 and to identify an optimal dose in subjects with mild to moderate psoriasis.
- Trial name
- NCT04603027
- Testing
- EDP1815
- Where
- 29 sites in United States, Hungary and 2 more
- Volunteers
- 249 people
- Sponsor
- Evelo Biosciences, Inc.
Plaque Psoriasis
Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis
This Phase 2 study has been designed to determine and compare the safety, tolerability, and efficacy of DUR-928 topical solution with that of the vehicle topical solution when applied once daily for approximately four weeks in…
- Trial name
- NCT03837743
- Testing
- DUR-928 Topical Solution, Vehicle Topical Solution
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Durect
Psoriasis
Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam
The purpose of the study is to compare the efficacy and safety of Clobetasol propionate to that of its Vehicle in the treatment of mild to moderate plaque-type psoriasis.
- Trial name
- NCT00842153
- Testing
- Clobetasol propionate foam, Vehicle foam
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Stiefel, a GSK Company
Psoriasis
AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis
The purpose of this study is to determine whether AN2728 topical ointment is a safe and effective treatment for mild-to-moderate plaque-type psoriasis.
- Trial name
- NCT01300052
- Testing
- AN2728 ointment, 2%, Ointment Vehicle
- Where
- 10 sites in United States
- Volunteers
- 68 people
- Sponsor
- Pfizer
Plaque Psoriasis
A Trial of a Botanical Drug (EISO) for Treatment of Mild-to-Moderate Plaque Psoriasis
This trial will be a double-blind, multi-center, randomized, placebo controlled study to evaluate the safety, tolerability, and efficacy of SAN021 study drug when administered for up to 42 days to adults between the ages of 18 to…
- Trial name
- NCT03000608
- Testing
- SAN021 Serum
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Santalis Pharmaceuticals, Inc.
Psoriasis Vulgaris
A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream
This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating efficacy, safety and convenience of the MC2-01 cream.
- Trial name
- NCT03308799
- Testing
- MC2-01 cream, Cal/BDP combination, Cream vehicle
- Where
- 3 sites in United States
- Volunteers
- 794 people
- Sponsor
- MC2 Therapeutics
Psoriasis
Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis
This is a Phase 2b, randomized, double blind, vehicle controlled, parallel group, multicenter study in participants with mild to moderate plaque psoriasis.
- Trial name
- NCT03850483
- Testing
- PF-06700841
- Where
- 79 sites in United States, Australia and 8 more
- Volunteers
- 344 people
- Sponsor
- Pfizer
Atopic Dermatitis, Plaque Psoriasis
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
The purpose of this clinical trial is to learn about the safety, how well the study medicine works, extent to which side effects can be tolerated, and how the study medicine is changed and eliminated from your body after you…
- Trial name
- NCT05375955
- Testing
- PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%
- Where
- 39 sites in United States, Canada and 2 more
- Volunteers
- 263 people
- Sponsor
- Pfizer
Plaque Psoriasis
Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)
The purpose of this study is to determine if calcipotriene/bethamethasone can safely and effectively manage the occurence of LMB (mild localized breakthrough) in patients recieving efalizumab (Raptiva) for moderate to severe…
- Trial name
- NCT00608777
- Testing
- Calcipotriene/betamethasone
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Derm Research, PLLC